--- title: "Septerna (SEPN) news: offering" url: "https://aibio.space/companies/septerna/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SEPN offering news: Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus. Septerna, Inc. (NASDAQ: SEPN), United States." --- SEPN Septerna, Inc. NASDAQ · United States # Septerna (SEPN) news SEPN offering news Financings · 2026-03-10 ## [Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus](https://aibio.space/news/septerna-files-automatic-shelf-150-000-000-atm-sales-agreement/) Septerna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain. ## Latest Septerna news We have not published a story on Septerna yet. When there is news, it will appear here. ## Septerna at a glance - **Ticker**: SEPN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $372.3 million ### Related companies - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [AquaBounty Technologies](https://aibio.space/companies/aquabounty-technologies/) NASDAQ: AQB - [NANOLOGIX INC](https://aibio.space/companies/nanologix/) OTC: NNLX - [Immunome](https://aibio.space/companies/immunome/) NASDAQ: IMNM - [Traws Pharma](https://aibio.space/companies/traws-pharma/) NASDAQ: TRAW - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) NASDAQ: AURA ### Also on NASDAQ - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) OBX - [Biodexa Pharmaceuticals](https://aibio.space/companies/biodexa-pharmaceuticals/) BDRX - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) RCKT - [TRINITY BIOTECH](https://aibio.space/companies/trinity-biotech/) TRIB - [DELCATH SYSTEMS, INC.](https://aibio.space/companies/delcath-systems/) DCTH - [Zhengye Biotechnology Holding](https://aibio.space/companies/zhengye-biotechnology/) ZYBT ## Septerna annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$46.0 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | | Research and development | [$97.6 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | [$65.3 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | | Net income (loss) | [-$48.9 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | [-$71.8 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | | Cash from operations | [$110.2 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | [-$67.5 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | | Cash and equivalents | [$120.7 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/) | [$238.2 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | | Short-term investments | [$270.4 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/) | [$112.7 million](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $84.7 million, plus short-term investments of $287.7 million, $372.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Septerna Has Septerna raised money recently? Our latest story on this, dated Mar 10, 2026: "Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/septerna-files-automatic-shelf-150-000-000-atm-sales-agreement/). What is the ticker symbol of Septerna? Septerna, Inc. trades under the ticker SEPN on NASDAQ. Where is Septerna listed? Septerna, Inc. is listed on NASDAQ. What is the SEC CIK of Septerna? The SEC Central Index Key (CIK) for Septerna, Inc. is 1984086. Its filings are on SEC EDGAR. How many shares does Septerna have outstanding? 46,676,947 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Septerna listed under? Our directory records Septerna, Inc. under United States. What does Septerna do? Our directory classifies Septerna, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Septerna? The ISIN recorded for Septerna, Inc. is US81734D1046. Does aibio.space cover Septerna? aibio.space lists Septerna, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Septerna incorporated? SEC records list its state or country of incorporation as DE. What was Septerna's revenue last year? $46.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Septerna profitable? Septerna, Inc. reported a net loss of $48.9 million for the fiscal year ended Dec 31, 2025, and generated $110.2 million of cash from operations, per its annual report to the SEC. How much does Septerna spend on research and development? $97.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Septerna have? $372.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Septerna (SEPN) stock news? Our latest story on Septerna, dated Mar 10, 2026: "Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus". Septerna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain. [Source](https://aibio.space/news/septerna-files-automatic-shelf-150-000-000-atm-sales-agreement/). ## Investor discussion: Septerna Members talk about Septerna (SEPN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Septerna, newest first. Each line links the filing it comes from. 1. 2026-03-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1984086/000119312526100234/d25619ds3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SEPN on TradingView](https://www.tradingview.com/symbols/NASDAQ-SEPN/). ## SEC filings and registration - **SEC name**: Septerna, Inc. - **CIK**: 1984086 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SEPN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-338-3533 - **Shares outstanding**: 46,676,947 as of 2026-08-05 (10-Q filed 2026-08-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1984086/000119312526364210/d172697d8k.htm) filed 2026-08-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1984086/000119312526290649/sepn-20260626.htm) filed 2026-06-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/sepn-20260511.htm) filed 2026-05-11 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1984086/000119312526197404/sepn-20260430.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504d8k.htm) filed 2026-04-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001984086), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Septerna, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SEPN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Septerna, Inc. - **Ticker**: SEPN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US81734D1046 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SEPN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/septerna/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Septerna (SEPN) news: offering", 2026-10-31, https://aibio.space/companies/septerna/